Ana Alfirevic, MD, PhD

Reviewing interests: Pharmacogenomics of drug safety, immune-mediated adverse drug reactions, cardiovascular pharmacogenetics, pharmacogenetics in reproductive medicine and pregnancy, implementation of personalised medicine into the clinic, pharmacogenetics and personalised medicine education

Ana is Professor of Pharmacology and Personalised Medicine and the Head of Department of Pharmacology and Therapeutics at the University of Liverpool. She is Elected Trustee of the British Pharmacological Society with responsibility for Senior Academic Leadership, Member of the steering committee for the European Pharmacogenomics Research and Implementation Network within the European Federation for Pharmaceutical Sciences and Member of the Genomics England Clinical Interpretation Partnership (GeCIP). She is Executive Editor of British Journal of Clinical Pharmacology and serves on the editorial board of Journal of Personalised Medicine. To date, she has published over 130 peer-reviewed research papers some of which are in high impact journals, e.g., NEJM, Nature, European Heart Journal, Nature Communications, etc.

Ana’s research over the last 10 years has been focused on molecular pharmacology and pharmacogenetics. She has been working on several projects on discovery of genetic predisposing factors for adverse drug reactions including drug-induced hypersensitivity, hepatotoxicity, antipsychotic drug-induced agranulocytosis and statin-induced myotoxicity using high throughput genotyping and sequencing methodologies. In collaboration with academia and industry, she has helped to develop a panel of HLA alleles with clinical decision support tool that can be utilised to predict, monitor, diagnose and prevent immune-mediated adverse drug reactions and interpret complex HLA allele results. In addition, she lead several pharmacology and systems biology projects in reproductive medicine and pregnancy including the multiomic approach to preterm birth within the Harris Centre for Preterm Birth. Common to these research themes is the aim to generate large amount of omics data integrated with clinical data to identify biomarkers that may be utilized in clinical practice for patient benefit.

Editorial Board
Terms of Appointment: April 2021 - March 2023